Evaluation of 111In labeled antibodies for SPECT imaging of mesothelin expressing tumors

Nuclear Medicine and Biology

Volumn 38, Issue 6, 2011, Pages 885-896

  Misri, Ripen ^a   Saatchi, Katayoun ^a   Ng, Sylvia S W ^a,b   Kumar, Ujendra ^a   Häfeli, Urs O ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Biodistribution; In 111; Mesothelin; Radiolabeled antibody; SPECT CT

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INDIUM 111; MESOTHELIN; MESOTHELIN MONOCLONAL ANTIBODY K1 I 111; MESOTHELIN MONOCLONAL ANTIBODY MB I 111; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY LABELING; ARTICLE; BINDING ASSAY; BLOOD; BRAIN; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; HEART; IMMUNOREACTIVITY; IN VITRO STUDY; INTERNALIZATION; INTESTINE; ISOTOPE LABELING; KIDNEY; LIVER; LOW DRUG DOSE; LUNG; MESOTHELIOMA; MOUSE; MUSCLE; NONHUMAN; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; STOMACH; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; INDIUM RADIOISOTOPES; MALE; MICE; NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; X-RAY MICROTOMOGRAPHY;

EID: 80051702323     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.02.013     Document Type: Article

References (45)

1. Wong H.H., Lemoine N.R. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009, 6:412-422.
2. Cubillos-Ruiz J.R., Fiering S., Conejo-Garcia J.R. Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol 2009, 5:1189-1192.
3. Brand R. The diagnosis of pancreatic cancer. Cancer J 2001, 7:287-297.
4. Armato S.G., Entwisle J., Truong M.T., Nowak A.K., Ceresoli G.L., Zhao B., et al. Current state and future directions of pleural mesothelioma imaging. Lung Cancer 2008, 59:411-420.
5. Forstner R. Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol 2007, 17:3223-3235.
6. Goel A., Batra S.K. Antibody constructs for radioimmunodiagnosis and treatment of human pancreatic cancer. Teratog Carcinog Mutagen 2001, 21:45-57.
7. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003, 30:247-258.
8. Brader P., Kelly K.J., Chen N., Yu Y.A., Zhang Q., Zanzonico P., et al. Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene. Clin Cancer Res 2009, 15:3791-3801.
9. 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model. Nucl Med Commun 2010, 31:380-388.
10. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008, 14:2999-3019.
11. Onda M., Willingham M., Nagata S., Bera T.K., Beers R., Ho M., et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res 2005, 11:5840-5846.
12. Hassan R., Ho M. Mesothelin targeted cancer immunotherapy. European Journal of Cancer 2008, 44:46-53.
13. Argani P., Iacobuzio-Donahue C., Ryu B., Rosty C., Goggins M., Wilentz R.E., et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001, 7:3862-3868.
14. Hassan R., Kreitman R.J., Pastan I., Willingham M.C. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005, 13:243-247.
15. Muminova Z.E., Strong T.V., Shaw D.R. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer 2004, 4:19.
16. Scholler N., Garvik B., Hayden-Ledbetter M., Kline T., Urban N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett 2007, 247:130-136.
17. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002, 43:693-713.
18. Chang K., Pastan I., Willingham M.C. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992, 50:373-381.
19. 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int J Cancer 1999, 80:559-563.
20. 99mTc. Am Biotechnol Lab 1990, 8:50-53.
21. Hnatowich D.J., Childs R.L., Lanteigne D., Najafi A. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J Immunol Methods 1983, 65:147-157.
22. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P.A. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984, 72:77-89.
23. 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 2009, 36:81-93.
24. Sato N., Hassan R., Axworthy D.B., Wong K.J., Yu S., Theodore L.J., et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med 2005, 46:1201-1209.
25. Loening A.M., Gambhir S.S. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003, 2:131-137.
26. Pelat T., Hust M., Thullier P. Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem 2009, 9:1633-1638.
27. Hassan R., Lerner M.R., Benbrook D., Lightfoot S.A., Brackett D.J., Wang Q.C., et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 2002, 8:3520-3526.
28. Chowdhury P.S., Viner J.L., Beers R., Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998, 95:669-674.
29. Eckelman W.C., Kilbourn M.R., Mathis C.A. Discussion of targeting proteins in vivo: in vitro guidelines. Nucl Med Biol 2006, 33:449-451.
30. Press O.W., Shan D., Howell-Clark J., Eary J., Appelbaum F.R., Matthews D., et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996, 56:2123-2129.
31. Maeda H., Wu J.C., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release 2000, 65:271-284.
32. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009, 50:974-981.
33. Nakamae H., Wilbur D.S., Hamlin D.K., Thakar M.S., Santos E.B., Fisher D.R., et al. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res 2009, 69:2408-2415.
34. Bera T.K., Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000, 20:2902-2906.
35. Couturier O., Supiot S., Degraef-Mougin M., Faivre-Chauvet A., Carlier T., Chatal J.F., et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 2005, 32:601-614.
36. Congdon C.C. The destructive effect of radiation on lymphatic tissue. Cancer Res 1966, 26:1211-1220.
37. Kurnick N.B., Nokay N. Changes induced in the mouse spleen by graded doses of total-body x-irradiation. Radiat Res 1962, 17:140-144.
38. Cobb L.M., Butler S.A. Treatment of the murine lymphoma A31 with intravenous, sterilized, 114mIn-loaded A31 cells. Radiother Oncol 1987, 10:217-230.
39. Hofer K.G. Biophysical aspects of Auger processes. Acta Oncol 2000, 39:651-657.
40. Tajima K., Hirama M., Shiomi K., Ishiwata T., Yoshioka M., Iwase A., et al. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma. Anticancer Res 2008, 28:3933-3936.
41. Johnston F.M., Tan M.C., Tan B.R., Porembka M.R., Brunt E.M., Linehan D.C., et al. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 2009, 15:6511-6518.
42. Pimm M.V. Circulating antigen: bad or good for immunoscintigraphy?. Nucl Med Biol 1995, 22:137-145.
43. Dillman R.O. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002, 20:3545-3557.
44. Kletting P., Meyer C., Reske S.N., Glatting G. Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling. Cancer Biother Radiopharm 2010, 25:279-287.
45. Waldmann T. ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters. Leuk Lymphoma 2003, 44(Suppl 3):S107-S113.